The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Review of major adverse effects of androgen‐deprivation therapy in men with prostate cancer
Open accessAbstract
Androgen‐deprivation therapy (ADT) is a common treatment for men with prostate cancer. Although ADT is effective at suppressing prostate‐specific antigen (PSA), stabilizing disease, alleviating symptoms in advanced disease, and potentially prolonging survival, it is not without serious side effects. However, to the authors' knowledge, there is lack of a systematic review of its major adverse effects to date. The authors of this report systematically reviewed and quantitatively assessed the literature on skeletal and cardiac side effects associated with ADT in men with prostate cancer. The PubMed database was searched for relevant published articles from 1966 to May 2008, and 683 articles were reviewed systematically from an original 20 different Medical Subject Heading search combinations. The focus of the review was on bone‐related and cardiovascular‐related outcomes. When appropriate, results were pooled from articles on specific adverse outcomes, summary risk estimates were calculated, and tests of heterogeneity were performed. Fourteen articles were identified that met inclusion criteria from the original 683 studies. Men who underwent ADT for prostate cancer had a significantly increased risk of overall fracture of 23% (summary relative risk, 1.23; 95% confidence interval [95% CI], 1.10‐1.38) compared with men who had prostate cancer but who did not undergo ADT. Furthermore, men who underwent ADT had a 17% increase in cardiovascular‐related mortality compared with men who did not undergo with ADT (summary hazards ratio, 1.17; 95% CI, 1.07‐1.29). Significant elevations in the risk of diabetes also were observed from 2 large studies. ADT was associated with an increased risk of skeletal fracture, incident diabetes, and cardiovascular‐related mortality, although the absolute risk of these events was low. Preventive measures against these adverse effects and careful assessment of patient's baseline health status should be considered. Cancer 2009. © 2009 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Huggins, C., & Hodges, C. V. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,855
Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09408-4 · Cited by 1,686
Bolla, M., Gonzalez, D., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., Gil, T., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707313370502 · Cited by 1,548
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455
Risk of Fracture after Androgen Deprivation for Prostate Cancer
Shahinian, V. B., Kuo, Y.-F., Freeman, J. L., & Goodwin, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041943 · Cited by 1,375
Androgen Deprivation Therapy for Prostate Cancer
Sharifi, N. (2005) · JAMA · doi:10.1001/jama.294.2.238 · Cited by 1,083
Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer
Smith, M. R., McGovern, F. J., Zietman, A. L., Fallon, M. A., Hayden, D. L., Schoenfeld, D. A., Kantoff, P. W., & Finkelstein, J. S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010845 · Cited by 696
Androgen Suppression and Radiation vs Radiation Alone for Prostate Cancer: A Randomized Trial
D’Amico, A. V., Chen, M.-H., Renshaw, A. A., Loffredo, M., & Kantoff, P. W. (2008) · JAMA · doi:10.1001/jama.299.3.289 · Cited by 690
(1997) · British Journal of Urology · doi:10.1046/j.1464-410x.1997.d01-6840.x · Cited by 654
SMITH, M. R., EASTHAM, J., GLEASON, D. M., SHASHA, D., TCHEKMEDYIAN, S., & ZINNER, N. (2003) · Journal of Urology · doi:10.1097/01.ju.0000063820.94994.95 · Cited by 650
Metabolic Syndrome in Men With Prostate Cancer Undergoing Long-Term Androgen-Deprivation Therapy
Braga-Basaria, M., Dobs, A. S., Muller, D. C., Carducci, M. A., John, M., Egan, J., & Basaria, S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9741 · Cited by 585
Adib, R., Anderson, J., Ashken, M. H., Baumber, C. D., CRA, B. D., BEYNON, L. L., Blaxland, J. W., Boag, V., Bolger, J., Boreham, J., et al. (1997) · Kent Academic Repository (University of Kent) · Cited by 551
Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer
Saigal, C. S., Gore, J. L., Krupski, T. L., Hanley, J., Schonlau, M., & Litwin, M. S. (2007) · Cancer · doi:10.1002/cncr.22933 · Cited by 542
Androgen Deprivation Therapy for Localized Prostate Cancer and the Risk of Cardiovascular Mortality
Tsai, H. K., D'Amico, A. V., Sadetsky, N., Chen, M.-H., & Carroll, P. R. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm168 · Cited by 520
D'Amico, A. V., Denham, J. W., Crook, J., Chen, M.-H., Goldhaber, S. Z., Lamb, D. S., Joseph, D., Tai, K.-H., Malone, S., Ludgate, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3369 · Cited by 501 · cited 1×
“Two of those studies were retrospective cohorts in design,(36,39) and 2 studies were randomized clinical trials.(40,41) The 2 FIGURE 1.”
BackgroundInsulin sensitivity during combined androgen blockade for prostate cancer
Smith, M. R., Lee, H., & Nathan, D. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2507 · Cited by 493
Damber, J.-E., & Aus, G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60729-1 · Cited by 418
Bone Loss after Initiation of Androgen Deprivation Therapy in Patients with Prostate Cancer
Greenspan, S. L., Coates, P., Sereika, S. M., Nelson, J. B., Trump, D. L., & Resnick, N. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0183 · Cited by 411
Basaria, S., Muller, D. C., Carducci, M. A., Egan, J., & Dobs, A. S. (2006) · Cancer · doi:10.1002/cncr.21642 · Cited by 394
Smith, M. R., Lee, W. C., Brandman, J., Wang, Q., Botteman, M., & Pashos, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.6908 · Cited by 366
National Practice Patterns and Time Trends in Androgen Ablation for Localized Prostate Cancer
Cooperberg, M. R., Grossfeld, G. D., Lubeck, D. P., & Carroll, P. R. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.13.981 · Cited by 329
Shahinian, V. B., Kuo, Y., Freeman, J. L., Orihuela, E., & Goodwin, J. S. (2005) · Cancer · doi:10.1002/cncr.20955 · Cited by 323
Survival Following Primary Androgen Deprivation Therapy Among Men With Localized Prostate Cancer
Lu-Yao, G. L. (2008) · JAMA · doi:10.1001/jama.300.2.173 · Cited by 315
Greenspan, S. L., Nelson, J. B., Trump, D. L., & Resnick, N. M. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-6-200703200-00006 · Cited by 302
Prostate Cancer Risk and Serum Levels of Insulin and Leptin: a Population-Based Study
Hsing, A. W., Chua, S., Gao, Y.-T., Gentzschein, E., Chang, L., Deng, J., & Stanczyk, F. Z. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.10.783 · Cited by 298
Insulin Resistance and Prostate Cancer Risk
Hsing, A. W., Gao, Y.-T., Chua, S., Deng, J., & Stanczyk, F. Z. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.1.67 · Cited by 242
Risk of Clinical Fractures After Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer
Smith, M. R., Boyce, S. P., Moyneur, E., Duh, M. S., Raut, M. K., & Brandman, J. (2006) · Journal of Urology · doi:10.1016/s0022-5347(05)00033-9 · Cited by 212
Efstathiou, J. A., Bae, K., Shipley, W. U., Hanks, G. E., Pilepich, M. V., Sandler, H. M., & Smith, M. R. (2008) · European Urology · doi:10.1016/j.eururo.2008.01.021 · Cited by 200
Androgen Deprivation Therapy in Prostate Cancer and Metabolic Risk for Atherosclerosis
Shahani, S., Braga-Basaria, M., & Basaria, S. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2595 · Cited by 185
Morote, J., Morin, J. P., Orsola, A., Abascal, J. M., Salvador, C., Trilla, E., Raventos, C. X., Cecchini, L., Encabo, G., & Reventos, J. (2007) · Urology · doi:10.1016/j.urology.2006.11.002 · Cited by 184
Alibhai, S. M. H., Gogov, S., & Allibhai, Z. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.06.006 · Cited by 173
Kiratli, B. J., Srinivas, S., Perkash, I., & Terris, M. K. (2001) · Urology · doi:10.1016/s0090-4295(00)00895-5 · Cited by 172
Shahinian, V. B. (2006) · Archives of Internal Medicine · doi:10.1001/.465 · Cited by 162
Ryan, C. W., Huo, D., Demers, L. M., Beer, T. M., Lacerna, L. V., & Zometa US05 Investigators (2006) · The Journal of Urology · doi:10.1016/j.juro.2006.04.078 · Cited by 127
Green, H. J., Pakenham, K. I., Headley, B. C., Yaxley, J. W., Nicol, D. L., MacTaggart, P., Swanson, C. E., Watson, R. B., & Gardiner, R. A. (2004) · British Journal of Urology · doi:10.1111/j.1464-410x.2004.04763.x · Cited by 121
International Trends in Prostate-Cancer Mortality: The Decrease is Continuing and Spreading
Baade, P. D., Coory, M. D., & Aitken, J. F. (2004) · Cancer Causes & Control · doi:10.1023/b:caco.0000024212.66334.26 · Cited by 109
Higano, C. S. (2008) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0995 · Cited by 109
Haidar, A., Yassin, A. A., Saad, F., & Shabsigh, R. (2007) · The Aging Male · doi:10.1080/13685530701653538 · Cited by 102
Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy
Braga‐Basaria, M., Muller, D. C., Carducci, M. A., Dobs, A. S., & Basaria, S. S. (2006) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3901471 · Cited by 101
Lage, M. J., Barber, B., & Markus, R. A. (2007) · Urology · doi:10.1016/j.urology.2007.08.012 · Cited by 89
Critical evaluation of hormonal therapy for carcinoma of the prostate
Chodak, G. W., Keane, T. E., & Klotz, L. H. (2002) · Urology · doi:10.1016/s0090-4295(02)01677-1 · Cited by 87
The Effect of Androgen Deprivation Therapy on Fasting Serum Lipid and Glucose Parameters
Yannucci, J., Manola, J., Garnick, M. B., Bhat, G., & Bubley, G. J. (2006) · The Journal of Urology · doi:10.1016/j.juro.2006.03.057 · Cited by 84
Fracture risk in Danish men with prostate cancer: a nationwide register study
Abrahamsen, B., Nielsen, M. F., Eskildsen, P. C., Andersen, J. T., Walter, S., & Brixen, K. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.07163.x · Cited by 78
Fracture risk in patients with prostate cancer on androgen deprivation therapy
López, A. M., Pena, M. Á., Hernández, R., Val, F., Martín, B., & Riancho, J. A. (2005) · Osteoporosis International · doi:10.1007/s00198-004-1799-7 · Cited by 75
Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss
Preston, D., Torréns, J. I., Harding, P., Howard, R. S., Duncan, W. E., & McLeod, D. G. R. (2002) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500599 · Cited by 69
Fred Saad, C. (2005) · Clinical Prostate Cancer · doi:10.3816/cgc.2005.n.009 · Cited by 63
Moróte, J., García, E. M., Trilla, E., Esquena, S., Junquera, J. M. A., Encabo, G., & Reventós, J. (2003) · European Urology · doi:10.1016/s0302-2838(03)00379-8 · Cited by 63
Estrogenic side effects of androgen deprivation therapy.
Guise, T. A., Oefelein, M. G., Eastham, J. A., Cookson, M. S., Higano, C. S., & Smith, M. R. (2007) · Europe PMC (PubMed Central) · Cited by 53
Holmes, L., Chan, W., Jiang, Z., & Du, X. L. (2007) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500973 · Cited by 38
Self-citationDecreasing mortality rates for prostate cancer: possible role of hormonal therapy?
Damber, J. (2004) · British Journal of Urology · doi:10.1111/j.1464-410x.2003.04713.x · Cited by 25
Basaria, S. S., Muller, D. C., Carducci, M. A., Egan, J. M., & Dobs, A. S. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.6.612 · Cited by 19
Cited by
American Cancer Society prostate cancer survivorship care guidelines
Skolarus, T. A., Wolf, A. M. D., Erb, N. L., Brooks, D. D., Rivers, B. M., Underwood, W., Salner, A. L., Zelefsky, M. J., Aragon‐Ching, J. B., Slovin, S. F., et al. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21234 · Cited by 398
Ost, P., Bossi, A., Decaestecker, K., De Meerleer, G., Giannarini, G., Karnes, R. J., Roach, M., & Briganti, A. (2015) · European Urology · doi:10.1016/j.eururo.2014.09.004 · Cited by 349
Long-Term and Latent Side Effects of Specific Cancer Types
Gegechkori, N., Haines, L., & Lin, J. J. (2017) · Medical Clinics of North America · doi:10.1016/j.mcna.2017.06.003 · Cited by 286
Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence
Decaestecker, K., De Meerleer, G., Lambert, B., Delrue, L., Fonteyne, V., Claeys, T., De Vos, F., Huysse, W., Hautekiet, A., Maes, G., et al. (2014) · Radiation Oncology · doi:10.1186/1748-717x-9-135 · Cited by 255
Gardner, J. R., Livingston, P. M., & Fraser, S. F. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.5523 · Cited by 243
Metadata
- Authors
- Taylor, L. G., Canfield, S. E., & Du, X. L.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2009-05-20
- Volume
- 115
- Issue
- 11
- Pages
- 2388-2399
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2073626999
- Cited by
- 324
- References
- 52
- FWCI
- 21.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.